Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of two 50 mg prolonged-release mirabegron tablet formulations under fed conditions in healthy Thai volunteers
TCTR20220223006Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of mirabegron in overactive bladder (OAB), sponsored by Novartis. Primary endpoints: AUC0-t of mirabegron, AUC0-inf of mirabegron and 3 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on TCTR20220223006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220223006.